<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitisinone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitisinone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nitisinone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10911" href="/d/html/10911.html" rel="external">see "Nitisinone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12644" href="/d/html/12644.html" rel="external">see "Nitisinone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F201700"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nityr;</li>
<li>Orfadin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867693"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>MDK-Nitisinone;</li>
<li>Orfadin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F201713"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        4-Hydroxyphenylpyruvate Dioxygenase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F201701"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Must be used in conjunction with a diet restricted in tyrosine and phenylalanine. Titrate dose as needed based on biochemical and/or clinical response. If the biochemical response is satisfactory, the dosage should be adjusted only according to body weight gain. Do not adjust dose according to plasma tyrosine concentration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98630151-0d12-4d69-8310-05b6f7954fa4">Hereditary tyrosinemia type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary tyrosinemia type 1 (HT-1):</b>
<b>Oral:</b> Initial: 0.5 mg/kg twice daily. Increase to 0.75 mg/kg twice daily if succinylacetone is detectable 4 weeks after initiation. Further increase may be needed based on the evaluation of all biochemical parameters (maximum dose: 2 mg/kg/day); dose may be administered once daily (eg, 1 to 2 mg/kg once daily) if serum and urine succinylacetone is undetectable after ≥4 weeks of therapy.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991990"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989226"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F201702"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F201708"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12644" href="/d/html/12644.html" rel="external">see "Nitisinone: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Must be used in conjunction with a diet restricted in tyrosine and phenylalanine. If using tablets, round calculated dose up to the nearest available tablet strength.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98630151-0d12-4d69-8310-05b6f7954fa4">Hereditary tyrosinemia type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hereditary tyrosinemia type 1 (HT-1):</b> Infants, Children, and Adolescents: Oral: Initial: 0.5 mg/kg/dose twice daily; titrate dose individually based on biochemical markers (eg, plasma and/or urine succinylacetone concentrations, liver function parameters and alpha-fetoprotein concentrations) and clinical response. If succinylacetone concentrations are still detectable after 1 month of therapy, may increase dose to 0.75 mg/kg/dose twice daily; may further increase as needed up to a maximum of 1 mg/kg/dose twice daily; maximum daily dose: 2 mg/kg/<b>day. </b>Once the biochemical response is satisfactory, further dosage adjustments should be only according to body weight gain; in patients ≥5 years using capsules or oral suspension, daily dose may be transitioned to once daily (eg, 1 to 2 mg/kg/dose once daily) if serum and urine succinylacetone is undetectable after ≥4 weeks of stable therapy.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51131207"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. The effect of renal dysfunction on the pharmacokinetics of nitisinone has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F51131208"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. The effect of hepatic dysfunction on the pharmacokinetics of nitisinone has not been studied.</p></div>
<div class="block adr drugH1Div" id="F201675"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in pediatric patients and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Increased plasma tyrosine</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (1%), exfoliative dermatitis (1%), maculopapular rash (1%), pruritus (1%), xeroderma (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Porphyria (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granulocytopenia (1%), leukopenia (3%), thrombocytopenia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (7%), hepatic neoplasm (malignant: 5%; benign: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (1%), cataract (1%), conjunctivitis (2%), corneal opacity (2%), eye pain (1%), keratitis (2%), photophobia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Enanthema</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, gastrointestinal hemorrhage, melena</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatomegaly, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Septicemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Brain neoplasm, encephalopathy, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, cyanosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastric distress</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal ulcer</p></div>
<div class="block coi drugH1Div" id="F201688"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to nitisinone or any component of the formulation; breastfeeding</p></div>
<div class="block war drugH1Div" id="F201673"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to hyperkeratotic plaques on the soles and palms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Leukopenia and/or thrombocytopenia have been reported; may improve with dose reduction. May be due to underlying liver disease rather than drug-related (McKiernan 2006). Monitor platelets and WBC regularly during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurological effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to variable degrees of intellectual disability and developmental delay; clinical laboratory assessment including tyrosine levels is recommended for any patient exhibiting abrupt changes in neurological status while on therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Failure to adequately restrict dietary tyrosine and phenylalanine may lead to ocular toxicities (eg, conjunctivitis, corneal ulcers, corneal opacities, eye pain, keratitis, photophobia). Slit-lamp examination of the eyes is recommended prior to initiation of therapy and regularly thereafter, and in patients who develop photophobia, eye pain, tyrosine levels &gt;500 mcmol/L, or signs of inflammation (eg, redness, swelling, burning of the eyes). Immediate measurement of plasma tyrosine concentration is also recommended in patients who develop ocular symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glycerol: Oral suspension contains 500 mg/mL of glycerol; oral doses of glycerol ≥10 g may cause headache, upset stomach, and diarrhea. Patients receiving single doses &gt;20 mL are at increased risk for these adverse reactions; consider switching patients unable to tolerate the oral suspension to nitisinone capsules.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dietary restrictions: Must be used with dietary restriction of tyrosine and phenylalanine; inadequate restriction can result in toxic effects to the eyes, skin, and nervous system. Evaluate plasma tyrosine concentrations in patients who develop signs and symptoms of toxicity. Nutritional consultation is recommended.</p></div>
<div class="block foc drugH1Div" id="F201683"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orfadin: 2 mg, 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Orfadin: 4 mg/mL (90 mL) [contains polysorbate 80, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nityr: 2 mg, 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F201670"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323495"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Nitisinone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $98.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $245.21 - $245.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $490.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $980.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Orfadin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $65.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $163.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $326.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $653.92</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Orfadin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL (per mL): $142.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Nityr Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $107.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $267.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $535.74</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867694"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg, 10 mg, 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/mL (90 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 5 mg, 10 mg</p></div>
<div class="block accres drugH1Div" id="F11234123"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Distributed by Orfadin4U comprehensive patient support program.  Information regarding acquisition of product may be obtained by calling 877-473-3179. Additional information can be found at http://www.orfadin.com
                  </p></div>
<div class="block adm drugH1Div" id="F201685"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Administer at least 1 hour prior to, or 2 hours after a meal. Capsules may be opened and contents suspended in a small quantity of water, formula, or apple sauce; administer immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Administer without regards to meals. Allow suspension to warm to room temperature (30 to 60 minutes) prior to preparation.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Administer without regards to meals. Tablets may be disintegrated in water and administered using an oral syringe or crushed and mixed with applesauce (administration with other liquids or foods is not recommended [has not been studied]). Refer to manufacturer's labeling for detailed instructions.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Applesauce administration: </i>Add ~1 teaspoonful of applesauce to clean glass container; crush 1 tablet at a time between two teaspoons forming a fine powder (repeat if &gt;1 tablet needed). Transfer all the powder to the applesauce; mix until well dispersed. Administer immediately or within 2 hours of mixing. Once administered, add ~1 teaspoon of applesauce to the same container and administer to ensure no powder is remaining.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Oral syringe administration: </i>Tablet(s) must be fully disintegrated prior to administering with an oral syringe; turn oral syringe up and down for ≥30 seconds prior to administering. To ensure full administration, leave a gap between the plunger and oral syringe; after administering fill oral syringe with 2 mL of water, shake well, and administer while fully depressing the plunger (repeat if particles are still present).</p></div>
<div class="block admp drugH1Div" id="F52613426"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer in divided doses in the morning and evening.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Administer at least 1 hour prior to, or 2 hours after a meal. Capsules may be opened and contents suspended in a small quantity of water, formula, or applesauce; use immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: May administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Administer without regard to meals. Tablets may be disintegrated in water and administered using an oral syringe or crushed and mixed with applesauce (administration with other liquids or foods is not recommended [has not been studied]). Refer to manufacturer's labeling for detailed instructions.</p></div>
<div class="block use drugH1Div" id="F201684"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hereditary tyrosinemia type 1:</b> Treatment of hereditary tyrosinemia type 1 (HT-1) as an adjunct to dietary restriction of tyrosine and phenylalanine in adult and pediatric patients.</p></div>
<div class="block cyt drugH1Div" id="F13299764"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2C9 (moderate), OAT1/3; <b>Induces</b> CYP2E1 (weak)</p></div>
<div class="block dri drugH1Div" id="F6221931"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic).  Management: Consider reducing the alitretinoin dose to 10 mg when used together with moderate CYP2C9 inhibitors. Monitor for increased alitretinoin effects/toxicities if combined with a moderate CYP2C9 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celecoxib: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Celecoxib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OAT1/3 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diclofenac (Systemic): CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Diclofenac (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Erdafitinib.  Management: Avoid concomitant use of erdafitinib and moderate CYP2C9 inhibitors when possible. If combined, monitor closely for erdafitinib adverse reactions and consider dose modifications accordingly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flurbiprofen (Systemic): CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Flurbiprofen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluvastatin: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Fluvastatin.  Management: Fluvastatin should be used at the lowest effective dose and should not exceed 20 mg twice daily when combined with moderate CYP2C9 inhibitors. Avoid coadministration of fluvastatin extended-release tablets with moderate CYP2C9 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Losartan: CYP2C9 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Losartan. CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Losartan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meloxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Meloxicam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nateglinide: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OAT1/3 Substrates (Clinically Relevant): Nitisinone may increase the serum concentration of OAT1/3 Substrates (Clinically Relevant). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Parecoxib: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Parecoxib. Specifically, serum concentrations of the active moiety valdecoxib may be increased.  Management: Use the lowest effective dose of parecoxib and consider a dose reduction in patients taking moderate CYP2C9 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Siponimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. Specifically, concentrations of tetrahydrocannabinol may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Torsemide: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Torsemide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F201697"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Effect of taking nitisinone capsules with food is unknown; administration of oral suspension with a high calorie and high fat meal decreased C<sub>max</sub> by ~20%, but did not affect AUC. Tyrosine toxicity can occur without proper dietary restriction of tyrosine and phenylalanine. Management: Administer capsules at least 1 hour prior to, or 2 hours after a meal; administer oral suspension without regard to meals. Dietary restriction of tyrosine and phenylalanine is required. </p></div>
<div class="block pri drugH1Div" id="F201690"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Nitisinone crosses the placenta (Kassel 2015; Medina 2020; Vanclooster 2012).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to use of nitisinone in pregnancy is limited. Dose adjustments may be needed as pregnancy progresses and again following delivery (Äärelä 2020; Kassel 2015; Medina 2020; Vanclooster 2012). Available consensus guidelines do not have recommendations related to use of nitisinone in pregnant patients. Infants exposed to nitisinone during pregnancy should be closely monitored (Chinsky 2017).</p></div>
<div class="block brc drugH1Div" id="F20617178"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if nitisinone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Case reports of nitisinone use in patients who are breastfeeding are limited (Medina 2020). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of exposure to the infant, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Available consensus guidelines consider breastfeeding to be contraindicated if the mother is treated with nitisinone. Children diagnosed with hereditary tyrosinemia type 1 should be treated with nitisinone as soon as possible following diagnosis (Chinsky 2017).</p></div>
<div class="block dic drugH1Div" id="F201691"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Nitisinone capsules should be taken at least 1 hour prior to, or 2 hours after a meal. Dietary restriction of tyrosine and phenylalanine is required.</p></div>
<div class="block mop drugH1Div" id="F201680"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Dietary tyrosine and phenylalanine (assess dietary intake with tyrosine concentrations &gt;500 mcmol/L); urine and/or plasma succinylacetone, liver function parameters, and alpha-fetoprotein levels; measure all biochemical markers (urine and/or plasma succinylacetone, urine 5-aminolevulinate, and erythrocyte porphobilinogen-synthase activity) at initiation, when switching from twice daily to once daily dosing, or if there is a deterioration of the patient's clinical condition; body weight; slit-lamp examination (prior to initiation of therapy and regularly thereafter, and in patients who develop symptoms of ocular toxicity or tyrosine concentrations &gt;500 mcmol/L); plasma tyrosine (as clinically indicated with side effects; concentrations should be kept &lt;500 mcmol/L to avoid toxicity); platelet and white blood cell counts (regularly during therapy). Detailed recommendations for monitoring developed by expert consensus are available (Chinsky 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Plasma succinylacetone may take up to 3 months to normalize after start of therapy (Holme 2000).</p></div>
<div class="block pha drugH1Div" id="F201672"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">In patients with HT-1, tyrosine metabolism is interrupted due to a lack of the enzyme (fumarylacetoacetate hydrolase) needed in the last step of tyrosine degradation. Toxic metabolites of tyrosine accumulate and cause liver and kidney toxicity. Nitisinone competitively inhibits 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme present early in the tyrosine degradation pathway, thereby preventing the build-up of the toxic metabolites. </p></div>
<div class="block phk drugH1Div" id="F201687"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Limited pharmacokinetic studies exist for children or HT-1 patients.</p>
<p style="text-indent:-2em;margin-left:2em;">V<sub>d</sub>: Healthy volunteers: 8.2 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minor metabolism possibly via CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Healthy volunteers: Terminal half-life: Capsule, suspension: 54 hours; Tablet: 59.3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Healthy volunteers:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule:</p>
<p style="text-indent:-2em;margin-left:6em;">Single 30 mg dose: Median: 3.5 hours (range: 0.8 to 8 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Multiple 80 mg doses: Median: 4 hours (range: 0 to 16 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Single 30 mg dose: Median: 0.4 hours (range: 0.2 to 4 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Single 10 mg dose: Median: 3.5 hours (range: 1 to 4 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Healthy volunteers: Urine (3% unchanged).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038706"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Nitine | Orfadin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone dipharma | Orfadin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Nitikabs</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Nitisinona | Nitisor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone dipharma | Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nitisinona dipharma | Orfadin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">N.t.b.c. | Nitisinone dipharma | Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone dipharma | Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone dipharma | Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone mdk | NTBC | Orfadin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone dipharma | Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone dipharma | Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone mdk | NTBC | Orfadin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nityr | Orfadin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Nitisinona mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ariquel | Orfadin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Nitisinone dipharm | Nitisinone mdk | Orfadin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Nitizyn | Orfadin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Tisinon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Orfadin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32238608">
<a name="32238608"></a>Äärelä L, Nevalainen PI, Kurppa K, Hiltunen P. First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia. <i>J Pediatr Endocrinol Metab</i>. 2020;33(5):661-664. doi:10.1515/jpem-2019-0540<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/32238608/pubmed" id="32238608" target="_blank">32238608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28771246">
<a name="28771246"></a>Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. <i>Genet Med</i>. 2017;19(12). doi:10.1038/gim.2017.101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/28771246/pubmed" id="28771246" target="_blank">28771246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11232358">
<a name="11232358"></a>Holme E, Lindstedt S. Nontransplant Treatment of Tyrosinemia. <i>Clin Liver Dis</i>. 2000;4(4):805-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/11232358/pubmed" id="11232358" target="_blank">11232358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23838819">
<a name="23838819"></a>Kassel R, Sprietsma L, Rudnick DA. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I. <i>J Pediatr Gastroenterol Nutr</i>. 2015;60(1):e5-e7. doi:10.1097/MPG.0b013e3182a27463<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/23838819/pubmed" id="23838819" target="_blank">23838819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16706549">
<a name="16706549"></a>McKiernan PJ. Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1. <i>Drugs</i>. 2006;66(6):743-750.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/16706549/pubmed" id="16706549" target="_blank">16706549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33300677">
<a name="33300677"></a>Medina MF, Arias C, Cabello JF, et al. Case report: maternal tyrosinemia type 1a under NTBC treatment with tyrosine- and phenylalanine restricted diet in Chile. <i>Am J Med Genet C Semin Med Genet</i>. 2020;184(4):1009-1013. doi:10.1002/ajmg.c.31863<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/33300677/pubmed" id="33300677" target="_blank">33300677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.1">
<a name="Par.1"></a>Nitisinone capsules [prescribing information]. Chestnut Ridge, NJ: Par Pharmaceutical; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Analog.1">
<a name="Analog.1"></a>Nitisinone capsules [prescribing information]. Princeton, NJ: Analog Pharma Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33300677">
<a name="33300677"></a>Nitisinone [product monograph]. Burlington, Ontario, Canada: CRI; June 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/33300677/pubmed" id="33300677" target="_blank">33300677</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nityr (nitisinone) [prescribing information]. Cambridge, UK: Cycle Pharmaceuticals; January 2024.</div>
</li>
<li>
<div class="reference">
                  Orfadin (nitisinone) [prescribing information]. Waltham, MA: Sobi Inc; November 2021.</div>
</li>
<li>
<div class="reference">
                  Orfadin (nitisinone) [Canadian product monograph]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23430914">
<a name="23430914"></a>Vanclooster A, Devlieger R, Meersseman W, et al. Pregnancy during nitisinone treatment for tyrosinaemia type I: first human experience. <i>JIMD Rep</i>. 2012;5:27-33. doi:10.1007/8904_2011_88<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitisinone-drug-information/abstract-text/23430914/pubmed" id="23430914" target="_blank">23430914</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10149 Version 213.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
